Renaissance School of Medicine Student on the Magic of the White Coat – Stony Brook News

On August 11, Jheison Giraldo 21, a third-year student in the Renaissance School of Medicine, delivered the student address to incoming students at the School of Medicines White Coat Ceremony. Giraldo, who immigrated to the United States from Colombia and is the first member of his family to graduate from college, spoke about his experience at Stony Brook and his advice for the Class of 2023.

What a privilege it is giving the student address today. It was exactly two years ago when I sat somewhere over there. I was so nervous that day that I barely remembered anything at all. Only a couple of things really stood out to me.

I remember being way too worried about tripping on my way up to the stage and aiming my arms correctly so that when they put on my white coat it would go on smoothly. You know, you have to look good up here.

Then, I remember taking steps across this stage, and when i turned to put on my white coat I heard my family cheer. I completely forgot about my arms and looked at my mom and brother.

I walked over to pick my new stethoscope, and I turned around and looked back, because right behind me was my wife.

I remember when we stood on this stage together, our families cheering THAT moment became one of my most cherished memories. I realized that this would be the beginning of an adventure for both of us, and what an adventure it has been.

I have watched a lot of movies and read a lot of books where the main character goes on an adventure, and they get one special item. Today, you start your adventure and you get one very special item. Its the white coat.

I dont know if they told you, but the white coat youre receiving has got magic. It will allow you to sleep the least amount youve ever slept before. Your focus will become 10 times as sharp. Your brain will be able to absorb more information than you have ever been able to hold, and your fingers will type as fast as the Flash when you are writing notes.

I am obviously joking, but the white coat gives you superpowers. It opens doors for research opportunities, and community outreach programs that would be impossible to get while you were pre-med. People actually listen to medical students.

The biggest power it has is with patients. Ive had patients tell me things they have never told their closest family members.

One patient told me about their suicide attempts. At the end of the conversation, they told me I was the first person they ever told that to.

Just last week, I saw a patient be strong for his family. He told them that he was going to be okay, and he was confident. Then, the family left and he broke down in tears. He told me about all of his fears; he told me he was afraid to die.

For some reason, the patients know that you will listen. They know that you are there to help them, that you will behave in a way that benefits them and upholds their values, and most importantly, that you are trustworthy. That is a superpower.

This is something that has been built by the people who have come before you. They have built an image of empathy, compassion, professionalism and altruism.

These are just a few of the qualities that make a good physician. When you put on that white coat, that is what it represents. It is important to think about that, when you are in the library, in the classroom, and in the hospital. You represent those who have come before you.

The power that Ive been talking about is in every thread of your white coat. Every physician adds another thread, and whether positive or negative, they shape the way that patients and communities see us.

It is a power that we all build together. In four years time, you will also add your thread to the white coat.

Now, I know it seems like a lot of responsibility and this is your first week but the next four years will prepare you for the future.

When those patients shared those things with me, all I could think was, Im just a medical student; why are you telling me these things? even though I knew I was prepared to handle those situations.

In all honesty, I have to say that we all have a little of that impostor syndrome, that feeling that we are not good enough or that we dont belong. You may think at some point after a hard week that someone made a mistake, they sent the acceptance to the wrong person. I joke with my wife about this. I say to her, Hey, they havent caught on to us yet. Even standing here today, Im asking, Why me?

My first thought is that I always say, Yes, so they knew I would show up. My second is that I can give you some perspective about success.

Im the first person in my family to graduate college. Im a Colombian immigrant that came from a family of farmers, raised by my mother who is a house cleaner and a brother who, instead of pursuing school himself, helped me in every way that he could.

I know firsthand how many barriers there are just to graduate college. I was one of the Student National Medical Association presidents. My knowledge of these barriers allowed me to teach those in our community who might face these same barriers how to overcome them.

I was part of a group of very committed medical students and faculty who brought hundreds of underserved students to this medical school, all in hopes that we can inspire them and help them get over these barriers.

Last year was the first year that one of our very own HOPE program graduates matriculated to medical school, and guess where they went? Thats right: they came here to the Renaissance School of Medicine.

I could go on about me, but my point is not to pay attention to what I have achieved but to pay attention to my first reaction. After I received this prestigious honor, I thought, Am I good enough? Despite all my success, its the question that I asked myself before every major achievement that I have had.

In this field, there will always be those moments of doubt. You will feel that you dont belong, or that you may not be good enough to reach your goals. Im here to tell you that its all a lie.

Hopefully, my perspective will help you in those moments of doubt, because if I can do this, so can you!

Fear of failure is what keeps us from achieving our highest potential, and this room is filled with potential. So, as you start your adventure/career, I have some pearls of wisdom that will help you along the way. Its seven things that have really helped me get through these last couple of years.

Now, I want you all to open your eyes and look around, see all these new faces around you.

These are the people who will be with you for the next four years. Its here in medical school that you will form lifelong bonds and friendships.

I want you to look at the faculty and alumni who are here to guide and support you as you grow into physicians, and I want you to look back at all of your family and friends who have helped you get you where you are today. This is the exercise that always helps me, because I know that I am not alone.

You have hundreds of people that you can rely on. We are a big family here, and its my pleasure to officially welcome you all to the Renaissance School of Medicine family.

Congratulations, Class of 2023.

Go here to see the original:

Renaissance School of Medicine Student on the Magic of the White Coat - Stony Brook News

Red Meat Intake and Cardiometabolic and Cancer Outcomes – Annals of Internal Medicine

McMaster University, Hamilton, Ontario, Canada (D.Z., J.B., K.C., K.M., B.S., Y.L., G.H.G.)

Dalhousie University, Halifax, Nova Scotia, Canada (B.C.J.)

Jagiellonian University Medical College, Krakw, Poland (M.M.B.)

Iberoamerican Cochrane Centre Barcelona, Biomedical Research Institute San Pau (IIB Sant Pau), Barcelona, Spain (C.V., M.R., P.A.)

University of British Columbia, Vancouver, British Columbia, Canada (D.S.)

University of Toronto, Toronto, Ontario, Canada (A.A.)

Clinica Las Americas, Medellin, Colombia (A.M.Z.)

Chosun University, Gwangju, Republic of Korea (M.A.H.)

Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, the Netherlands (R.W.V.)

Institute of Science and Technology, Universidade Estadual Paulista, So Jos dos Campos, So Paulo, Brazil (R.E.)

Acknowledgment: The authors thank Thomasin Adams-Webber (Hospital for Sick Children) for her help designing our search strategy.

Disclosures: Dr. El Dib received a So Paulo Research Foundation (FAPESP) (2018/11205-6) scholarship and funding from the National Council for Scientific and Technological Development (CNPq) (CNPq 310953/2015-4) and the Faculty of Medicine, Dalhousie University. Authors not named here have disclosed no conflicts of interest. Disclosures can also be viewed at http://www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M19-0622.

Editors' Disclosures: Christine Laine, MD, MPH, Editor in Chief, reports that her spouse has stock options/holdings with Targeted Diagnostics and Therapeutics. Darren B. Taichman, MD, PhD, Executive Editor, reports that he has no financial relationships or interests to disclose. Cynthia D. Mulrow, MD, MSc, Senior Deputy Editor, reports that she has no relationships or interests to disclose. Jaya K. Rao, MD, MHS, Deputy Editor, reports that she has stock holdings/options in Eli Lilly and Pfizer. Catharine B. Stack, PhD, MS, Deputy Editor, Statistics, reports that she has stock holdings in Pfizer, Johnson & Johnson, and Colgate-Palmolive. Christina C. Wee, MD, MPH, Deputy Editor, reports employment with Beth Israel Deaconess Medical Center. Sankey V. Williams, MD, Deputy Editor, reports that he has no financial relationships or interests to disclose. Yu-Xiao Yang, MD, MSCE, Deputy Editor, reports that he has no financial relationships or interest to disclose.

Reproducible Research Statement:Study protocol: Available at PROSPERO (CRD42017074074). Statistical code and data set: Available from Dr. Johnston (e-mail, bjohnston@dal.ca).

Corresponding Author: Bradley C. Johnston, PhD, Department of Community Health and Epidemiology, Dalhousie University, Centre for Clinical Research, Room 404, 5790 University Avenue, Halifax, Nova Scotia B3H 1V7, Canada; e-mail, bjohnston@dal.ca.

Current Author Addresses: Ms. Zeraatkar, Ms. Bartoszko, nad Drs. Sadeghirad and Guyatt: Department of Health Research Methods, Evidence, and Impact, McMaster University, 1280 Main Street West, Hamilton, Ontario L8S 4K1, Canada.

Dr. Johnston: Department of Community Health and Epidemiology, Dalhousie University, Centre for Clinical Research, Room 404, 5790 University Avenue, Halifax, Nova Scotia, B3H 1V7, Canada.

Dr. Cheung: 114 Loganberry Crescent, Toronto, Ontario M2H 3H1, Canada.

Dr. Bala: Jagiellonian University Medical College, 7 Kopernika Street, 31-034 Krakw, Poland.

Ms. Valli and Drs. Rabassa and Alonso-Coello: Iberoamerican Cochrane Centre, Instituto de Investigacin Biomdica de Sant Pau (IIB Sant Pau-CIBERESP), Carrer de Sant Antoni Maria Claret 167, Barcelona 08025, Spain.

Dr. Sit: University of British Columbia, 107-1165 West 13th Avenue, Vancouver, British Columbia V6H 1N4, Canada.

Mr. Milio: 592 Regal Place, Waterloo, Ontario N2V 2G3, Canada.

Dr. Agarwal: Department of Medicine, University of Toronto, Suite RFE 3-805, 200 Elizabeth Street, Toronto, Ontario M5G 2C4, Canada.

Mr. Lee: 30 White Lodge Crescent, Richmond Hill, Ontario L4C 9A1, Canada.

Ms. Zea: Clinica Las Americas, Diagonal 75B N. 2A-80/140, Medellin, Colombia.

Dr. Han: Department of Preventive Medicine, College of Medicine, Chosun University, 309 Philmun-daero, Dong-gu, Gwangju 61452, Korea.

Dr. Vernooij: Department of Research, Netherlands Comprehensive Cancer Organisation, Godebaldkwartier 419, Utrecht 3511 DT, the Netherlands.

Dr. El Dib: Institute of Science and Technology, So Jos dos Campos, Avenida Engenheiro Francisco Jos Longo, 777, Jardim So Dimas, So Paulo 12245-000, Brazil.

Author Contributions: Conception and design: D. Zeraatkar, B.C. Johnston, M.M. Bala, P. Alonso-Coello, G.H. Guyatt, R. El Dib.

Analysis and interpretation of the data: D. Zeraatkar, B.C. Johnston, M.M. Bala, M. Rabassa, D. Sit, M.A. Han, P. Alonso-Coello, G.H. Guyatt, R. El Dib.

Drafting of the article: B.C. Johnston, R. El Dib.

Critical revision of the article for important intellectual content: D. Zeraatkar, B.C. Johnston, M.M. Bala, D. Sit, B. Sadeghirad, A.M. Zea, Y. Lee, M.A. Han, R.W.M. Vernooij, P. Alonso-Coello, G.H. Guyatt, R. El Dib.

Final approval of the article: D. Zeraatkar, B.C. Johnston, J. Bartoszko, K. Cheung, M.M. Bala, C. Valli, M. Rabassa, D. Sit, K. Milio, B. Sadeghirad, A. Agarwal, A.M. Zea, Y. Lee, M.A. Han, R.W.M. Vernooij, P. Alonso-Coello, G.H. Guyatt, R. El Dib.

Provision of study materials or patients: B.C. Johnston, R. El Dib.

Administrative, technical, or logistic support: D. Zeraatkar, B.C. Johnston, R. El Dib.

Collection and assembly of data: D. Zeraatkar, B.C. Johnston, J. Bartoszko, K. Cheung, M.M. Bala, C. Valli, M. Rabassa, D. Sit, K. Milio, B. Sadeghirad, A. Agarwal, A.M. Zea, Y. Lee, M. Han, R.W.M. Vernooij, R. El Dib.

Read more:

Red Meat Intake and Cardiometabolic and Cancer Outcomes - Annals of Internal Medicine

Does the Married to Medicine Cast Keep in Touch with Quad Webb’s Ex-Husband? – Bravo

The cast members of Married to Medicine aren't just friends; they're practically family. So when Quad Webb and Dr. Gregory Lunceford decided to get divorced last season, it naturally had an impact on the group.

But did the end of this marriage mean the end of Dr. Gregory's friendships with the group? Dr. Jackie Walters confirmed that her husband, Curtis Berry, and Dr. Heavenly Kimes' husband, Dr. Damon Kimes, still have a relationship with Dr. Gregory today during the ladies' appearance on Watch What Happens Live with Andy Cohen Sunday night (clip above).

Dr. Jackie and Dr. Heavenly also noted that they're cool with that. "It doesn't matter to me," Dr. Heavenly said.

The Married to Medicine OBGYN provided some more insight into Curtis' friendship with Dr. Gregory during an interview with The Daily Dish on Monday, September 30 in New York City, sharing that they bonded over their love of golf in the past, so they still keep in touch. "It is absolutely not difficult to have my husband be friends with Greg because we don't talk about the two," Dr. Jackie said.

Dr. Heavenly echoed that sentiment during a separate interview with The Daily Dish on Monday. "Damon and Greg actually refer patients back-and-forth, so they're friends and they have a professional relationship. So yeah, he does speak to Greg once in a while," she said. "I've never had really a relationship with any of the men, so no, it makes no difference to me. I think Damon has friends with the men, and I kind of stay separate with the women."

Mariah Huq also told The Daily Dish during an interview earlier this month that she and her husband,Dr. Aydin Huq, don't keep in touch with Dr. Gregory at all these days. "But if I see him, I would speak [to him], hug him," she said. "I have no problems with him at all."

Quad shared in September 2018that she had filed for divorce from Dr. Gregory. The Daily Dish confirmed in August that the couple's divorce is finalized.

Watch Quad open up about her divorce this season ofMarried to Medicine, below.

Preview

Was Quad Webb "Pinned to the Cross" by the Ladies During Her Divorce?

See the original post here:

Does the Married to Medicine Cast Keep in Touch with Quad Webb's Ex-Husband? - Bravo

Novartis and Microsoft announce collaboration to transform medicine with artificial intelligence – GlobeNewswire

The digital press release with multimedia content can be accessed here:

Basel, and Redmond, October 1, 2019 Novartis today announced an important step in reimagining medicine by founding the Novartis AI innovation lab and by selecting Microsoft as its strategic AI and data-science partner for this effort. The new lab aims to bolster Novartis AI capabilities from research through commercialization and help accelerate the discovery and development of transformative medicines for patients worldwide.

As part of the strategic collaboration announced, Novartis and Microsoft have committed to a multi-year research and development effort. This strategic alliance will focus on two core objectives:1) AI Empowerment. The lab will aim to bring the power of AI to the desktop of every Novartis associate. By bringing together vast amounts of Novartis datasets with Microsofts advanced AI solutions, the lab will aim to create new AI models and applications that can augment our associates capabilities to take on the next wave of challenges in medicine.2) AI Exploration. The lab will use the power of AI to tackle some of the hardest computational challenges within life sciences, starting with generative chemistry, image segmentation & analysis for smart and personalized delivery of therapies and optimization of cell and gene therapies at scale.

Microsoft and Novartis will also collaborate to develop and apply next-generation AI platforms and processes that support future programs across these two focus areas. The overall investment will include project funding, subject-matter experts, technology, and tools.

Vas Narasimhan, CEO of Novartis, said, As Novartis continues evolving into a focused medicines company powered by advanced therapy platforms and data science, alliances like this will help us deliver on our purpose to reimagine medicine to improve and extend patients lives. Pairing our deep knowledge of human biology and medicine with Microsofts leading expertise in AI could transform the way we discover and develop medicines for the world.

Microsoft CEO, Satya Nadella, added, Our strategic alliance will combine Novartis' life sciences expertise with the power of Azure and Microsoft AI. Together, we aim to address some of the biggest challenges facing the life sciences industry today and bring AI capabilities to every Novartis employee so they can unlock new insights as they work to discover new medicines and reduce patient costs.

Novartis Data & Digital Novartis is focusing itself as a leading medicines company powered by advanced therapies and data science. Going big on data and digital is a key strategic pillar that helps Novartis realize that ambition. Data science and digital technologies allow the company to reimagine how to innovate in R&D, engage with patients and customers, and increase operational efficiencies. Novartis focuses its efforts around four strategic digital priority areas:1) Scaling 12 digital lighthouse projects: Build a strong foundation and jumpstart our digital transformation2) Make Novartis digital: sharing, learning and talent acquisition3) Becoming the #1 partner in the tech ecosystem: bridge Novartis with external expertise4) Bolder moves: lead through future disruptive healthcare scenarios with large-scale partnerships

DisclaimerThis press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 that can generally be identified by words such as to transform, multiyear, commitment, to found, aims, vision, potential, can, will, plan, expect, anticipate, committed, or similar terms, or regarding the development or adoption of potentially transformational technologies and business models and the collaboration with Microsoft; or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the healthcare products described in this press release, or regarding potential future revenues from collaboration with Microsoft or such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the collaboration with Microsoft will achieve any or all of its intended goals or objectives, or in any particular time frame. Neither can there be any guarantee that any healthcare products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that the collaboration with Microsoft or such products will be commercially successful in the future. In particular, our expectations regarding the collaboration with Microsoft and such products could be affected by, among other things, uncertainties involved in the development or adoption of potentially transformational technologies and business models; the uncertainties inherent in research and development of new healthcare products, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally, including potential regulatory actions or delays with respect to the collaboration with Microsoft; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and trade conditions; safety, quality or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AGs current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About NovartisNovartis is reimagining medicine to improve and extend peoples lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the worlds top companies investing in research and development. Novartis products reach more than 750 million people globally and we are finding innovative ways to expand access to our latest treatments. About 108 000 people of more than 140 nationalities work at Novartis around the world. Find out more at http://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartisnewsFor Novartis multimedia content, please visit http://www.novartis.com/news/media-libraryFor questions about the site or required registration, please contact media.relations@novartis.com

About MicrosoftMicrosoft (Nasdaq MSFT @microsoft) enables digital transformation for the era of an intelligent cloud and an intelligent edge. Its mission is to empower every person and every organization on the planet to achieve more.

# # #

Novartis Media RelationsE-mail: media.relations@novartis.com

Novartis Investor RelationsCentral investor relations line: +41 61 324 7944E-mail: investor.relations@novartis.com

See more here:

Novartis and Microsoft announce collaboration to transform medicine with artificial intelligence - GlobeNewswire

When Music Is the Best Medicine – The New York Times

Ms. Caudill and I then went to a conference room to discuss music therapy with my husband, Don, and our friend Alexandra, who has engaged in music ministry. Music must be an especially effective form of therapy, Don supposed, because it directly expresses and creates emotions. Alexandra agreed. Singing in a choir for and with people impaired by dementia, she has witnessed elderly men and women who could not remember their own names recalling verbatim the words of beloved hymns.

Music lights up neurons between the right and left hemispheres of the brain, Ms. Caudill said. It can also aid in neuroplasticity, helping the brain form new connections. A stress reliever, music is used to recover speech, improve walking and assist in the retrieval of memories. Popular and classical melodies can be infinitely modified to meet various backgrounds and tastes.

[Read more about the use of music for mental health.]

Sometimes depressed patients are encouraged to compose new lyrics to a favorite song that can then convey their reactions to their condition. Ms. Caudill recorded a lymphoma patient singing her version of Shawn Mendess In My Blood and upon discharge gave her an MP3 of her new anthem: Sometimes I feel I should give up, but I cant. It isnt in my blood.

Others strum the reverie harp with Ms. Caudill or hum while she accompanies on guitar. She has drummed with relatives awaiting a family members medical decisions. One man asked for help choosing music for his own memorial; Ms. Caudill calls this legacy work and adds that it also involves facilitating life review, reminiscing and aiding in the clarification of values and beliefs through discussions of song lyrics.

In Oliver Sackss Musicophilia: Tales of Music and the Brain, the renowned neurologist drew on the enormous and rapidly growing body of work on the neural underpinnings of musical perception and imagery that started to evolve in the 1980s. It seeks to explain why those with brain injuries, epilepsy, Alzheimers, Parkinsons, autism and strokes may respond powerfully and specifically to music (and, sometimes, to little else). With these misfortunes, as with cancer, rhythms and harmonies can deliver Proustian mnemonics, giving patients access to lost words and worlds. Or they can simply provide the solace of auditory pleasure when few other delights can be experienced or recalled.

Professionals like Ms. Caudill meet the spiritual, psychological or aesthetic needs of the afflicted by producing sounds testifying to the fact that beauty continues to exist in the world. Witnessing people in circumstances that have conspired to warp their sensory faculties and to reduce them to passivity, music therapists offer patients perhaps the only activity conceivable that of listening as a pathway to becoming sensate and thus incontestably attuned to the animating realization of still being alive and responsive.

Music has worked for me as a fail-safe sedative. During a fraught 17-day stay in the hospital because of post-surgical infections 10 years ago, Beethovens Cavatina furnished the only moments during which I was released from suffering. Don had brought me the CD, along with a portable disk player.

Follow this link:

When Music Is the Best Medicine - The New York Times

For Homeless Californians, The Doctor Is Often The ER Street Medicine Aims To Change That – KPBS

Instead of trying to powerwash the problem away, Californias hospitals, public health departments, and homeless service organizations are increasingly sending trained health practitioners into homeless encampments in a quest to improve health outcomes for individual homeless people.

Aired: September 30, 2019 | Transcript

Dr. Coley King of the Venice Family Clinic is one of a growing number of medical professionals making house calls to the homeless.

Instead of trying to powerwash the problem away, Californias hospitals, public health departments, and homeless service organizations are increasingly sending trained health practitioners into homeless encampments in a quest to improve health outcomes for individual homeless people.

Western medicine is very much built around the ideal care for the ideal patient. Most of these folks are not in the ideal situation, said King. We can make some compromises that still do good medical care and get them to a very good average. It's better to take half of your medicine than none of your medicine.

One late September day, King makes a house call on Shawnda Thornton, a homeless woman in her late 40s living on the sidewalk across the street from a Silicon Beach tech campus in Venice.

OK, how are you feeling now on these medications? he asked her.

I love these medications because I'm not tired. I don't have to sleep all day. I can walk around and manage myself just like I used to, she responded.

Thornton has congestive heart failure, and September is the first month this year that she hasnt been hospitalized.

The goal King has for Thornton is to ensure she has access to ongoing medical care that keeps her out of the hospital. He thinks a lot of the public discussion that revolves around Californias crisis of homelessness misses the individual people who are physically deteriorating because they lack shelter.

The pitfall of labeling it a public health crisis is it becomes a reactionary not-in-my-backyard issue, said King. Thats not what this is about. This is about the individuals who are sicker than the rest of us, and who are dying sooner than the rest of us.

Homelessness Has A Body Count

The reality of Californias homelessness crisis is that it has a body count. Life expectancy for those who are living outside is about 30 years shorter than those who are housed. The median age of death outside is about 52.

The most comprehensive study of mortality on the street available comes from Boston. It found that two of the three most common causes of death were heart disease and cancer.

Los Angeles County, the epicenter of the states homelessness crisis, is expected to see more than 1,000 people die while experiencing homelessness this year. Last year the number was 921. In Orange County in 2018, it was 210; San Francisco, 135;. Sacramento, 132.

Distinct from the plainly human toll, the amount of money spent on the medical care of the sickest homeless people, many who eventually die on the street or in the hospital care, is mind-bogglingly high.

A 2016 study found that L.A. County spent nearly $400 million in one year on its so-called frequent flyers the 5 percent of the homeless population in poorest health who most frequently cycle through publicly operated institutions like jails and hospitals. A RAND estimate placed the individual cost per person for another particularly sick study group around $38,000 annually. Neither of those estimates includes insurance costs typically paid out by Californias Medi-Cal program.

A Futility Merry-Go-Round

Corrine Feldman of USCs Keck School of Medicine studies health care for homeless patients. She calls the persistent cycle of emergency hospitalizations a futility merry-go-round.

We all sort of end up on this seemingly never-ending merry-go-round together, and no one feels good about it, said Feldman. The ER provider who's seen the same person five times in the last five shifts, recognizes wholeheartedly that the plan that they have is not going to work, the patient is going to come back, and around we go again on the merry-go-round.

There is some, but relatively limited, evidence that shows doctors deployed to homeless encampments directly reduces public health care expenditures. There are also patient-centered studies that show regular visits from health practitioners has been shown to increase homeless patients engagement with primary care and behavioral care services.

Street medicine has been a vehicle to stop the merry-go-round a little bit, Feldman said. If we do this differently, and look at the problem differently, and tackle it together, we can at least maybe slow down the merry-go-round. Maybe we can stop it all together.

The logistics of how street medicine teams are funded and deployed varies from county to county. In the case of Los Angeles, county agencies dole out grants to free clinics, hospitals, and contracts health providers directly to provide street outreach. Hospitals and other foundations also offer to fund programs too. On a typical weekday, L.A. county officials say there are 38 outreach teams of doctors, nurse practitioners, physician assistants and mental health professions out working.

That means theyre providing basic primary care, basic psychiatry, enrolling people in Medi-Cal insurance, setting referral appointments and arranging transportation for homeless individuals to clinics.

Street medicine is practiced in most California counties where there is street homelessness. Besides Los Angeles County, San Francisco, San Mateo, Santa Clara, Alameda, Ventura, San Diego, Santa Barbara, Riverside, and Sacramento counties have dedicated public or private funding for some health-oriented homeless outreach.

Earlier this year, Orange Countys CalOptima health system proposed earmarking $100 million for homeless health care, including street medical teams.

But the process to do so has been complicated after objections from local hospitals. They argued in an August 2019 letter to CalOptima that not including private hospitals in the planning process would inevitably hamstring the effort.

The health system first proposed the project after learning that three-quarters of the 210 homeless people who died in Orange County in 2018 were enrolled in CalOptima.

The Street Is No Place To Heal

The challenge for CalOptima is the same confounding public health officials across the state; How do you get quality medical care to people who neither have shelter, money, nor (typically), transportation?

According to advocates, street medicine is a first step to proactively including people in a health care system that otherwise excludes them until the last possible minute. Dr. King says street medicine is a start, but what he really pines for is the ability to write a prescription for a patient for a housing unit with affordable rent.

My novel intervention for all the illness that comes with chronic homelessness would be affordable housing, said King. But right now, I'm left with trying to give good health care to these folks, trying to find them, engage them and make them welcome in my clinic.

As for his patient, Shawnda Thornton, when it comes to getting off the street, shes actually doing better than most. After more than three years of waiting, she obtained a Section 8 housing voucher. Her challenge now is finding a place to use it. While shes had several appointments to meet with property managers, she hasnt been able to because shes been so sick.

Every time I had an appointment, I would be in the hospital, said Thornton.

Which means now her voucher is close to expiring, Dr. Kings job is to make sure she stays on her meds, stays out of the hospital, and has time to actually find a place where she can heal that isnt a red nylon tent.

You can work on it, its certainly a place to start working. But to fully heal out here, I dont think its possible, Thornton said.

Editor's note: In an earlier web and radio version of this story, we said the Venice Family Clinic is free. In fact it is a community clinic that offers low-cost medical care.

The California Dream Project is a statewide collaboration focused on issues of economic opportunity, quality-of-life, and the future of the California Dream. Partner organizations include CALmatters, Capital Public Radio, KPBS, KPCC, and KQED.

To view PDF documents, Download Acrobat Reader.

Read the rest here:

For Homeless Californians, The Doctor Is Often The ER Street Medicine Aims To Change That - KPBS

Editas Medicine to Participate in Upcoming Investor Conferences – GlobeNewswire

CAMBRIDGE, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will participate in the following upcoming investor conferences:

Cell & Gene Meeting on the MesaPanel: What does the future hold for gene editing?Date: Friday, October 4, 2019Time: 9:45 a.m. PT

Chardan 3rd Annual Genetic Medicines ConferenceDate: Monday, October 7, 2019

Fireside ChatTime: 10:30 a.m. ET

Panel: Whats next in gene editing technologies?Time: 12:45 p.m. ETLocation: New York, NY

The events will be webcast live and may be accessed on the Editas Medicine website in the Investors and Media section. Archived recordings will be available for approximately 30 days following the events.

About Editas MedicineAs a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 (also known as Cas12a) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit http://www.editasmedicine.com.

Contacts:InvestorsMark Mullikin(617) 401-9083mark.mullikin@editasmed.com

MediaCristi Barnett(617) 401-0113 cristi.barnett@editasmed.com

See the original post:

Editas Medicine to Participate in Upcoming Investor Conferences - GlobeNewswire

American University of the Caribbean School of Medicine Offers Medical School Scholarships to Canadians – Business Wire

PEMBROKE PINES, Fla.--(BUSINESS WIRE)--With an ongoing doctor shortage in Canada, American University of the Caribbean (AUC) School of Medicine is providing scholarships of approximately $73,000 (CAD) per student for Canadians accepted to the university.

Currently, more than 150 Canadian students attend AUC School of Medicine, the overwhelming majority of whom received scholarships totaling more than four million Canadian dollars. Over the past two decades, the school has helped hundreds of Canadians become practicing physicians, many with the help of scholarships.

Our medical students from Canada, whether they choose to study at our campus in Sint Maarten or at our new campus in the U.K., are important assets to our community at AUC School of Medicine. They take advantage of the opportunities for community engagement, and many take on leadership roles within the student body, said Dr. Heidi Chumley, executive dean of AUC School of Medicine. Many wish to return to Canada to practice and help address crucial healthcare workforce and access issues, such as the doctor shortage.

While 15% of Canadians aged 12 and older dont have a regular healthcare provider1, the problem is much worse in in rural regions, which attract just 10% of the nations doctors.2

The AUC School of Medicine Canadian scholarship is available to incoming Canadian students who qualify, and is renewable each semester when the student maintains good academic standing. To learn more visit: aucmed.edu.

About American University of the Caribbean School of Medicine

American University of the Caribbean School of Medicine (AUC School of Medicine) is an institution of Adtalem Global Education (NYSE: ATGE), a global education provider headquartered in the United States. AUC School of Medicines mission is to train tomorrows physicians, whose service to their communities and their patients is enhanced by international learning experiences, a diverse learning community, and an emphasis on social accountability and engagement. Founded in 1978, AUC School of Medicine has more than 7,000 graduates, many of whom work in primary care or underserved areas. Dedicated to developing physicians with a lifelong commitment to patient-centered care, AUC School of Medicine embraces collaboration, inclusion and community service. With a campus in Sint Maarten, affiliated teaching hospitals in the United States and the United Kingdom, and internationally recognized faculty, AUC School of Medicine has a diverse medical education program for todays globally minded physician. For more information visit aucmed.edu, follow AUC School of Medicine on Twitter (@aucmed), Instagram (@aucmed_edu) and Facebook (@aucmed).

About Adtalem Global Education

The purpose of Adtalem Global Education is to empower students to achieve their goals, find success and make inspiring contributions to our global community. Adtalem Global Education Inc. (NYSE: ATGE; member S&P MidCap 400 Index) is a leading workforce solutions provider and the parent organization of Adtalem Educacional do Brasil (IBMEC, Damsio and Wyden institutions), American University of the Caribbean School of Medicine, Association of Certified Anti-Money Laundering Specialists, Becker Professional Education, Chamberlain University, EduPristine, OnCourse Learning, Ross University School of Medicine and Ross University School of Veterinary Medicine. For more information, please visit adtalem.com and follow us on Twitter (@adtalemglobal) and LinkedIn.

1 Statistics Canada, 2018 Data2 Review of family medicine within rural and remote Canada: education, practice, and policy, 2016.

See the original post here:

American University of the Caribbean School of Medicine Offers Medical School Scholarships to Canadians - Business Wire

Durango Diaries to host session on alternative medicine – The Durango Herald

Durango Diaries, the biweekly storyteller series hosted by The Durango Herald, is back Wednesday, as three local health care practitioners share stories about alternative medicine.

The event will be held at 6 p.m. at Durango Public Library, 1900 East Third Ave.

Speakers will include:

Teresa Jantz, owner of Touchpoint Therapy LLC, who has been practicing Reiki for 10 years, including angelic, crystal and animal Reiki, as well as being a master teacher and practitioner. Reiki brings about inner peace, happiness and optimal health for her students and clients.

Sydney Cooley, a licensed acupuncturist. Before becoming a Chinese medicine practitioner, she worked in criminal justice and with emotionally disturbed adolescents. That work inspired her to help people heal through holistic medicine.

Dr. Nicola Dehlinger, a naturopathic doctor with Pura Vida Natural Healthcare. An expert in the treatment of anxiety, depression and insomnia, she minimizes supplements and medications by empowering her patients to heal themselves.Season 4 of Durango Diaries will continue through November at 6 p.m. Wednesdays at the Durango library. Upcoming event topics are:

Oct. 16: How you can save the environment. Local environmental advocates will share stories about how small movements can grow. Bears Ears advocate Regina Lopez-Whiteskunk, Great Old Broads for the Wilderness Executive Director Shelley Silbert, city of Durango Sustainability Coordinator Imogen Ainsworth and advocate of eco-friendly business practices and Durango Cannabis Co. co-founder Nic Borst will share their stories.

Nov. 6: Photography. Three photographers will share the stories behind their favorite photographs and how they work to create the perfect frame. Storytellers include portrait and wedding photographer Allison Ragsdale, nature photographer Frank Comisar and Herald photographer Jerry McBride.

Nov. 20: Forever young. As our population ages, no one seems to be slowing down. Three retirees who are still pursuing active lifestyles will share their stories. Speakers include National Senior Games swimmer Kathy Kronwall, 82; Pilates instructor Diane Legner, 80; and skiing expert Major Lefebvre, 70.

The podcast of each Durango Diaries, including past seasons, can be heard on iTunes, Spotify or the Heralds website at durangoherald.com/durangodiaries.

To receive the Durango Diaries newsletter, email durangodiaries@durangoherald.com.

Read the original here:

Durango Diaries to host session on alternative medicine - The Durango Herald

Medicines for the Many – Jacobin magazine

In the UK and across the world, patients are being denied medicines because of a system that prioritizes profits before lives. Labour announced bold policies this week to tackle the immediate crisis in medicines prices as well as transform a fundamentally broken system and re-orientate it to serve public health.

For decades, Big Pharma has decided what medicines get produced and who gets them. They can get away with charging the highest prices because new drugs are awarded twenty-year patents which mean that no other company can make or sell that drug during that period. With no competition, they can charge whatever price they like.

High prices have long been a problem for low and middle income countries but in recent years, prices are so high that rich countries like the UK are also struggling to afford these extortionate rates. Our National Health Service increasingly has to ration or reject effective treatments because they are just too expensive.

Luis Walkerfeatured inJeremy Corbyns speech at the party conference this week. This nine-year-old boy with cystic fibrosis has been campaigning to access a drug called Orkambi, which could slow down the progression of the disease and add years to his life. But the drug isnt available on the NHS in England because it is too expensive.And even after three years of negotiations, the drug maker Vertex is refusing to lower the eye-watering 105,000 price tag.

Sadly, Luis case isnt unique. But it does tell a powerful story about the failings of an innovation system whose products are supposed to support health and well-being. Instead, driven by profit and shareholder value, medicines are produced based on their projected financial returns rather than the priorities of public health. And so, even though we are facing an impending global antibiotics crisis, there has been barely any investment in developing new antibiotics. It is simply an unprofitable venture.

There is also insufficient investment into conditions that affect people living in the Global South, again because these markets are considered not lucrative enough. Pharmaceutical companies spend more on marketing and buying back their own shares than they do in research and development. All of this points to system that does not recognize health as a human right.

In the UK, people treasure the principle of public healthcare for all, free at the point of use, but privatized medicine undermines the values of universality. We desperately need greater public control over medicines to ensure that we have a health innovation system that delivers for public health. And this is exactly what Jeremy Corbyn has announced this week.

The package of measures contained in Medicines for the Many couldnt have come sooner. The proposals include the willingness to use compulsory licensing, a legal mechanism that allows a government to override a patent and permits other companies to produce a medicine at lower prices for the benefit of public health. The World Trade Organization and the World Health Organization recognize that intellectual property rights are not absolute and actively supports governments to use this right to address public health needs. A compulsory license on Orkambi could break the current deadlock and allow Luis and other patients to access this crucial treatment.

And thats just for starters. The public sector plays a significant role in funding research and development. Some estimates say thatbetween one- to two-thirdsof upfront health research globally is funded by the public purse. But there are no safeguards in the system to ensure that medicines developed with public money will benefit the public.

Instead, too often public research is bought up by private companies who go on to develop and market the drugs at high prices. Leaving the public to pay twice, first for the research and then in high prices. Its a classic example of socializing risks while privatizing rewards. As part of the reform package, Labour will include conditions on public funding to ensure that drugs developed with public research are affordable for the NHS.

Finally, Labour is supporting democratic public ownership of drug development and manufacturing capabilities. Manufacturing generic drugs especially those that are in shortage or in areas that are deemed unprofitable will enable future governments to determine and deliver on public health priorities.

This transformative agenda recognizes that access to medicines is crucial to achieving the right to health for all. Its about taking the bold steps to re-orientate the system so that it delivers for public health.

Over many years, the power of Big Pharma has gone largely unchallenged as they have stitched up global rules and constructed for themselves a legal architecture of intellectual property rights and market exclusivities to protect their profits at the expense of patients. Now its time for the pendulum to swing the other way and it looks like Labour will lead the way to start building a pharmaceutical system where saving lives is the priority.

Continued here:

Medicines for the Many - Jacobin magazine

New England Journal of Medicine publishes data showing improved survival with Jevtana (cabazitaxel) over second androgen receptor-targeted agent in…

PARIS, Sept. 30, 2019 /PRNewswire/ --Data published today in the New England Journal of Medicine showed that patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel and who progressed within 12 months on an androgen receptor (AR)-targeted agent (abiraterone or enzalutamide) experienced significantly longer radiographic progression free survival (rPFS) with Jevtana (cabazitaxel) plus prednisone compared with abiraterone plus prednisone or enzalutamide. Overall survival (OS) with Jevtanawas also significantly longer. These findings from the CARD study were presented today in the Presidential Symposium of the 2019 European Society of Medical Oncology (ESMO) Congress in Barcelona, Spain.

"In this study, treatment with Jevtana significantly improved radiographic progression free survival and overall survival compared with enzalutamide or abiraterone," said Professor Ronald de Wit from Erasmus MC University Hospital, Rotterdam, The Netherlands, and the lead investigator of the CARD study."These results are exciting as they have the potential to impact treatment guidelines for metastatic prostate cancer and current clinical practice."

CARD is a randomized, open-label, treatment sequencing clinical study involving 62 sites across 13 European countries, enrolling 255 patients (median aged 70 years, 31% aged over 75 years) with mCRPC who were previously treated with docetaxel and who progressed within 12 months on an AR-targeted agent,in any order. These patients were randomized 1:1 to Jevtana (25 mg/m2 intravenously every three weeks, daily prednisone, and granulocyte colony-stimulating factor) versus abiraterone (1,000 mg plus prednisone, daily) or enzalutamide (160 mg daily; patients received abiraterone if they were previously treated with enzalutamide, or enzalutamide if they were previously treated with abiraterone).

CARD study met primary and secondary endpoints

The study's primary endpoint was rPFS, which more than doubled with Jevtana treatment (N=129) compared to abiraterone or enzalutamide (N=126; median 8.0 vs 3.7 months; HR=0.54; 95% CI,0.400.73; p<0.0001). Patients treated with Jevtana experienced an improvement in rPFS in all pre-specified subgroups, irrespective of the timing of the previous alternative AR-targeted agent, before or after docetaxel. Jevtana also significantly improved a key secondary endpoint, OS (median 13.6 vs 11.0 months; HR=0.64; 95%CI, 0.460.89; p=0.0078), reducing the risk of death from any cause by 36% compared with abiraterone or enzalutamide. Other key secondary endpoints all favored Jevtana: progression-free survival (PFS) (median 4.4 vs 2.7 months; p<0.0001); confirmed prostate specific antigen (PSA) (35.7% vs 13.5%; p=0.0002) and tumor responses (36.5% vs 11.5%; p=0.004). Pain response (45.0% vs 19.3%; p<0.0001) and time to symptomatic skeletal events (not reached vs 16.7 months, p=0.0499) were also significantly improved with Jevtana treatment.

The incidence of grade 3 adverse events was (56.3% with Jevtana vs 52.4% with AR-targeted agents). Key grade 3 treatment-emergent adverse events with Jevtana versus AR-targeted agents were renal disorders (3.2% vs 8.1%), infections (7.9% vs 7.3%), musculoskeletal pain/discomfort (1.6% vs 5.6%), cardiac disorders (0.8% vs 4.8%), asthenic conditions (4.0% vs 2.4%), diarrhea (3.2% vs 0), peripheral neuropathy (3.2% vs 0) and febrile neutropenia (3.2% vs 0). Serious adverse event rates of any grade were similar for Jevtana treatment (38.9%) and treatment with an AR-targeted agent (38.7%). AEs led to death in 7 vs 14 patients (5.6% vs 11.3%) for Jevtana compared to AR-targeted agents. No new safety signals were observed.

About Prostate Cancer

Prostate cancer is a very heterogenous disease and one of the most common types of cancer in men.1 Prostate cancer is the second leading cause of cancer related death among men in the United States2 and the third in Europe.3

Metastatic castration-resistant prostate cancer (mCRPC) is prostate cancer that has spread beyond the prostate gland and progressed despite androgen deprivation therapy.

About Jevtana (cabazitaxel)

Jevtana is a semi-synthetic taxane chemotherapy. Jevtana is a microtubule inhibitor that binds to tubulin. This leads to the stabilization of microtubules, which results in the inhibition of mitotic and interphase cellular functions.

U.S. INDICATION

JEVTANA is a prescription anti-cancer medicine used with the steroid medicine prednisone. JEVTANA is used to treat men with castration-resistant prostate cancer (prostate cancer that is resistant to medical or surgical treatments that lower testosterone) that has worsened (progressed) after treatment with other medicines, including docetaxel.

IMPORTANT SAFETY INFORMATION FOR U.S. PATIENTS

What is the most important information I should know about JEVTANA?

JEVTANA may cause serious side effects, including:

Low white blood cells,which can cause you to get serious infections, and may lead to death. Men who are 65 years or older may be more likely to have these problems. Yourhealthcareprovider (HCP):

Tell your HCP right away if you have any of these symptoms of infection during treatment with JEVTANA:fever (take your temperature often during treatment with JEVTANA), cough, burning during urination, or muscle aches.

Also, tell your HCP if you have any diarrhea during the time that your white blood cell count is low. Your HCP may prescribe treatment for you as needed.

Severe allergic reactionscan happen within a few minutes after your infusion of JEVTANA starts, especially during the first and second infusions. Your HCP should prescribe medicines before each infusion to help prevent severe allergic reactions.

Tell your HCP right away if you have any of these symptoms of a severe allergic reaction during or soon after an infusion of JEVTANA:rash or itching, skin redness, feeling dizzy or faint, breathing problems, chest or throat tightness, or swelling of face.

JEVTANA can cause severe stomach and intestine problems, which may lead to death. You may need to go to the hospital for treatment.

Vomiting and diarrhea can happen when you receive JEVTANA. Severe vomiting and diarrhea with JEVTANA can lead to loss of too much body fluid (dehydration), or too much of your body salts (electrolytes). Death has happened from having severe diarrhea and losing too much body fluid or body salts with JEVTANA. Your HCP will prescribe medicines to prevent or treat vomiting and diarrhea, as needed with JEVTANA.

Tell your HCP if:you have vomiting or diarrhea, or if your symptoms get worse or do not get better. JEVTANA can cause a leak in the stomach or intestine, intestinal blockage, infection, and bleeding in the stomach or intestine. This can lead to death.Tell your HCP if you get any of these symptoms:severe stomach-area (abdomen) pain, constipation, fever, blood in your stool, or changes in the color of your stool.

Kidney failuremay happen with JEVTANA, because of severe infection, loss of too much body fluid (dehydration), and other reasons, which may lead to death. Your HCP will check you for this problem and treat you if needed.

Tell your HCP if you develop these signs or symptoms:swelling of your face or body, or decrease in the amount of urine that your body makes each day or blood in your urine.

Lung or breathing problemsmay happen with JEVTANA and may lead to death. Men who have lung disease before receiving JEVTANA may have a higher risk for developing lung or breathing problems with JEVTANA treatment. Your HCP will check you for this problem and treat you if needed.

Tell your HCP right away if you develop any new or worsening symptoms, including: trouble breathing, shortness of breath, chest pain, cough or fever.

Who should not receive JEVTANA?

Do not receive JEVTANA if:your white blood cell (neutrophil count) is too low, you have had a severe allergic reaction to cabazitaxel or other medicines that contain polysorbate 80 (ask your HCP if you are not sure), you have severe liver problems or you are pregnant. JEVTANA can harm your unborn baby or possibly cause loss of pregnancy.

What should I tell my HCP before receiving JEVTANA?Before receiving JEVTANA, tell your HCP if you:

JEVTANA may cause fertility problems in males. This may affect your ability to father a child. Talk to your HCP if you have concerns about fertility.

Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. JEVTANA can interact with many other medicines. Do not take any new medicines without asking your HCP first. Your HCP will tell you if it is safe to take the new medicine with JEVTANA.

What are the possible side effects of JEVTANA?

Common side effects of JEVTANA include:

Tell your HCP if you have any side effect that bothers you or that does not go away.These are not all the possible side effects of JEVTANA. For more information, ask your HCP or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at1-800-FDA-1088.

Please see fullPrescribing Information/Patient Information, including Serious Side Effects.

About Sanofi

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Sanofi, Empowering Life

Media Relations Contact

Investor Relations Contact

Ashleigh Koss

George Grofik

Tel.: +1 908-981-8745

Tel.: +33 (0)1 53 77 45 45

Ashleigh.Koss@sanofi.com

ir@sanofi.com

Sanofi Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic conditions, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2018. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements

1https://www.who.int/en/news-room/fact-sheets/detail/cancer

2Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7-34.

3Malvezzi M, Carioli G, Bertuccio P, et al. European cancer mortality predictions for the year 2019 with focus on breast cancer. Ann Oncol. 2019;30(5):781-787

SAUS.CAB.19.09.4971

SOURCE Sanofi

http://www.sanofi.us

The rest is here:

New England Journal of Medicine publishes data showing improved survival with Jevtana (cabazitaxel) over second androgen receptor-targeted agent in...

Take this medicine, and tell me about a day in your life – AAMCNews

A few years ago, I was working as an attending physician on the inpatient floor of Barnes-Jewish Hospital in St. Louis, Missouri. Barnes-Jewish is the teaching hospital for Washington University School of Medicine in St. Louis, and its a wonderful hospital, with highly competent and compassionate doctors, nurses, and other health care professionals.

But treating patients there was hard and often demoralizing, for the patients and for us. Thats because despite all of the tools at our disposal the latest technology, the best medicines, a compassionate and caring staff many patients just werent getting better. They would come in to see us and we would fix their immediate problem, but because of their social circumstances or where they lived or worked or limitations in their access to healthy food or affordable medications, they kept returning again and again.

I remember one patient, a 50-year-old woman with Type 2 diabetes who kept being readmitted to the hospital because her sugars were too high. She knew and we knew that a healthy diet and regular exercise would help her better control her blood sugar and reduce the amount of medication she needed. But she lived in a part of the city that was plagued by gun violence. Furthermore, she had no local grocery stores and got most of her food from a nearby 7-Eleven. She also worked two jobs, so she had no time to cook, shop for healthier foods, or exercise.

Those were the circumstances of her life, and they negatively affected the course of her disease.

As a physician, when your patients keep coming back to the hospital again and again, it can be frustrating. But understanding why they keep coming back can make you a better doctor.

I remember another patient, a man in his 60s with congestive heart failure, who often failed to show up for his regular appointments. When he got too sick, he would come to the emergency room. Turns out that this patient lived independently but had no car, so he would have to take three buses to get to the clinic. He had severe arthritis, so his mobility was even further limited. He often cut back on his medications, thinking that if he just took half his dose, he might be able to stretch out the interval between clinic visits. When he shared this information, it allowed the social worker to better connect him with community resources and help him make his appointments.

As a physician, when your patients keep coming back to the hospital again and again, it can be frustrating. But understanding why they keep coming back the social determinants that cause them to miss appointments or cut their medications in half or struggle to eat better and exercise more can make you a better doctor.

On Sept. 12, Stanley Goldfarb, MD, former associate dean of curriculum at the Perelman School of Medicine at the University of Pennsylvania, wrote an opinion piece for the Wall Street Journal lamenting medical schools incorporation of social justice issues in medical education. Goldfarb stated, incorrectly, that medical schools teach about social inequities, gun violence, climate change, and bias at the expense of rigorous scientific knowledge about the underpinnings and treatment of disease.

This is just not true. I have had the privilege of visiting medical schools and talking with medical educators around the country. Our educators are teaching the foundational sciences, they are teaching the social determinants of health, they are teaching how to communicate with diverse patients. They are doing all of this well, and they continually strive to do it all better.

A more diverse and culturally responsive physician workforce, and an understanding of the behavioral, psychological, and social determinants of health, are critically important to educating not only good but great physicians.

As medical educators, our responsibility is to teach future physicians to provide the best possible care for their patients and to improve the health of all. This means making sure they have the medical and scientific knowledge they need, as well as an understanding of environmental and social factors that affect a patients health. To suggest that medical education cannot or should not do both creates a false dichotomy.

Medical education has advanced to keep pace with rapid developments in medicine and science. We also know our patients health is inextricably linked to their environments, their communities, and the social fabrics of their lives. A more diverse and culturally responsive physician workforce, and an understanding of the behavioral, psychological, and social determinants of health, are critically important to educating not only good but great physicians.

So, too, is the ability of doctors to listen to, and communicate with, their patients. As new doctors avow in the Hippocratic Oath, I will remember that there is an art to medicine as well as science, and that warmth, sympathy, and understanding may outweigh the surgeons knife or the chemists drug.

Our profession is grounded in the human interaction between doctor and patient. The next generation of physicians must have not just the comprehensive skills and knowledge needed to care for their patients, but the ability to understand and empathize with them.Our patients deserve this, our learners want this, and our educators are working hard to meet these needs.

Visit link:

Take this medicine, and tell me about a day in your life - AAMCNews

Woman says her medicine is being taken away with vaping ban – WCVB Boston

A Massachusetts woman says the statewide vaping ban will severely affect her ability to function.Felicia Sagner has had severe, debilitating pain and migraines since she was involved in a car crash four years ago.The wife and mother of two said the pain was so paralyzing, she was practically stuck on her couch for two years. She struggled to find a form of treatment that eased it until she tried vaping medical marijuana."Things like CBD and THC, when used properly, can cure anything from a little sleeplessness to severe migraine pain," Sagner said."All of a sudden, I had my wife back -- for the first time in two years," said her husband, Daniel Sagner.When state officials banned all vaping products in Massachusetts on Tuesday, including THC, the Sagners stocked up. However, Felicia Sagner fears that her personal cure may vanish."How dare you," she said. "This was my medicine."The temporary ban came after a growing number of mysterious illnesses in America, including 805 lung injuries and 12 deaths across 10 states, were linked to vaping. Health officials said 77% of those patients had vaped THC before they exhibited symptoms.The Massachusetts vaping ban is a tough outcome for those like Felicia Sagner who vape medical marijuana, but Gov. Charlie Baker believes the health risks associated with vaping are too high at this time to continue to allow it.He declared a public health emergency, which temporarily banned the sale of all vaping products in the state for the next four months."In this particular case, until we know more about the short-term impact of vaping on certain people, I don't consider it to be a safe alternative," Baker said.Sagner, however, believes vaping is safer for her children when it comes to secondhand smoke and says vaping lets her control her dosage."You get exactly what you need when you need it," she said. "If you ingest an edible, it usually kind of hits you when you're least expecting it."Baker thinks four months is enough time for doctors to determine what's making people sick, but Sagner hopes answers to the health crisis come sooner than that."What he banned was the vape oil, which gave me the freedom to be a mother," she said.

A Massachusetts woman says the statewide vaping ban will severely affect her ability to function.

Felicia Sagner has had severe, debilitating pain and migraines since she was involved in a car crash four years ago.

The wife and mother of two said the pain was so paralyzing, she was practically stuck on her couch for two years. She struggled to find a form of treatment that eased it until she tried vaping medical marijuana.

"Things like CBD and THC, when used properly, can cure anything from a little sleeplessness to severe migraine pain," Sagner said.

"All of a sudden, I had my wife back -- for the first time in two years," said her husband, Daniel Sagner.

When state officials banned all vaping products in Massachusetts on Tuesday, including THC, the Sagners stocked up. However, Felicia Sagner fears that her personal cure may vanish.

"How dare you," she said. "This was my medicine."

The temporary ban came after a growing number of mysterious illnesses in America, including 805 lung injuries and 12 deaths across 10 states, were linked to vaping. Health officials said 77% of those patients had vaped THC before they exhibited symptoms.

The Massachusetts vaping ban is a tough outcome for those like Felicia Sagner who vape medical marijuana, but Gov. Charlie Baker believes the health risks associated with vaping are too high at this time to continue to allow it.

He declared a public health emergency, which temporarily banned the sale of all vaping products in the state for the next four months.

"In this particular case, until we know more about the short-term impact of vaping on certain people, I don't consider it to be a safe alternative," Baker said.

Sagner, however, believes vaping is safer for her children when it comes to secondhand smoke and says vaping lets her control her dosage.

"You get exactly what you need when you need it," she said. "If you ingest an edible, it usually kind of hits you when you're least expecting it."

Baker thinks four months is enough time for doctors to determine what's making people sick, but Sagner hopes answers to the health crisis come sooner than that.

"What he banned was the vape oil, which gave me the freedom to be a mother," she said.

Read the original here:

Woman says her medicine is being taken away with vaping ban - WCVB Boston

New UCI study explains the molecular mechanism of botanical folk medicines used to treat hypertension – Newswise

MEDIA CONTACT

Available for logged-in reporters only

Proceedings of the National Academy of Sciences (PNAS)

Newswise Irvine, Calif. September 30, 2019 Common herbs, including lavender, fennel and chamomile, have a long history of use as folk medicines used to lower blood pressure. In a new study, University of California, Irvine researchers explain the molecular mechanisms that make them work.

Published today in Proceedings of the National Academy of Sciences (PNAS), the study illustrates how many of the known traditional botanical plants used to lower blood pressure activate a specific potassium channel (KCNQ5) in blood vessels. KCNQ5, together with other potassium channels including KCNQ1 and KCNQ4, is expressed in vascular smooth muscle. When activated, KCNQ5 relaxes blood vessels, making it a logical mechanism for at least part of the hypotensive actions of certain botanical folk medicines.

We found KCNQ5 activation to be a unifying molecular mechanism shared by a diverse range of botanical hypotensive folk medicines. Lavandula angustifolia, commonly called lavender, was among those we studied. We discovered it to be among the most efficacious KCNQ5 potassium channel activators, along with fennel seed extract and chamomile, said Geoff Abbott, PhD, professor of physiology and biophysics at the UCI School of Medicine and senior investigator on the study.

Interestingly, the KCNQ5-selective potassium channel activation feature found in the botanicals is lacking in the modern synthetic pharmacopeia. Until now, it seems to have eluded conventional screening methods utilizing chemical libraries, which may account for why it is not a recognized feature of synthetic blood pressure medications.

Our discovery of these botanical KCNQ5-selective potassium channel openers may enable development of future targeted therapies for diseases including hypertension and KCNQ5 loss-of-function encephalopathy, said Abbott.

Documented use of botanical folk medicines stretches back as far as recorded human history. There is DNA evidence, dating back 48,000 years, that suggests the consumption of plants for medicinal use by Homo neanderthalensis. Archaeological evidence, dating back 800,000 years, even suggests non-food usage of plants by Homo erectus or similar species. Today, evidence of the efficacy of botanical folk medicines ranges from anecdotal to clinical trials, however the underlying molecular mechanisms often remain elusive.

This study was supported by the National Institutes of Health, National Institute of General Medical Sciences and the National Institute of Neurological Disorders and Stroke. Also involved in the study were UCIs Ran Manville, PhD, PhD student Kaitlyn Redford and Benjamin Katz, PhD, and from the University of Copenhagen, Denmark, PhD student Jennifer van der Horst and Thomas Jepps, PhD.

About the UCI School of Medicine: Each year, the UCI School of Medicine educates more than 400 medical students, as well as 200 doctoral and masters students. More than 600 residents and fellows are trained at UC Irvine Medical Center and affiliated institutions. The School of Medicine offers an MD; a dual MD/PhD medical scientist training program; and PhDs and masters degrees in anatomy and neurobiology, biomedical sciences, genetic counseling, epidemiology, environmental health sciences, pathology, pharmacology, physiology and biophysics, and translational sciences. Medical students also may pursue an MD/MBA, an MD/masters in public health, or an MD/masters degree through one of three mission-based programs: the Health Education to Advance Leaders in Integrative Medicine (HEAL-IM), the Leadership Education to Advance Diversity-African, Black and Caribbean (LEAD-ABC), and the Program in Medical Education for the Latino Community (PRIME-LC). The UCI School of Medicine is accredited by the Liaison Committee on Medical Accreditation and ranks among the top 50 nationwide for research. For more information, visit som.uci.edu.

Go here to read the rest:

New UCI study explains the molecular mechanism of botanical folk medicines used to treat hypertension - Newswise

10 Things Nurses Would Never Keep In Their Medicine Cabinets – HuffPost

Some items in your medicine cabinet are staples that belong there, like a first aid kit, tweezers and eye drops. But are there some items that shouldnt be stored in your bathroom cupboard?

Medical experts say yes. We surveyed nurses to get their take on what they would never keep in their own medicine cabinets and why you shouldnt either. Their answers may surprise you.

1. Makeup thats beyond its expiration date

Caiaimage/Tom Merton via Getty Images

Repeated use of expired makeup, especially foundation and eyeliners, can cause infection, said Sandy Cayo, a clinical assistant professor of nursing at New York Universitys Rory Meyers College of Nursing. She added that with every use of expired makeup, you increase the chances of bacterial growth and in turn breakouts and infections.

Your makeup products should have an expiration date listed on the packaging, but in the event that they dont, here is a rough guideline as to how long things should last:

2. Narcotics

Any drug that you dont want into the hands of kids or home guests should be stored somewhere more secure than a medicine cabinet, said Teri Dreher, a registered nurse and owner of NShore Patient Advocates in Chicago.

Dreher said narcotics, in particular, should be under lock and key, or safely hidden. (Examples of these include medications like codeine and oxycodone.) And when theyre no longer needed, they should be disposed of at special boxes at pharmacies or police stations.

There is a nationwide opioid epidemic and you can never be more careful that narcotics do not end up in the wrong hands, Dreher explained.

Its also a good idea to get rid of any narcotics that are expired and you no longer need. If you have been treated for an injury or a surgery and were prescribed narcotics but didnt use them all, they should be properly disposed, explained Ashley Cook, the patient safety manager at Avista Adventist Hospital in Louisville Colorado.

3. Medications

Not storing your medications in a medicine cabinet may sound counterintuitive, but Gail Trauco, a patient advocate and CEO of medical retail store The PharmaKon LLC in Atlanta, doesnt recommend keeping them there.

All medications have [expiration] dates and temperature storage requirements, Trauco said, adding that it can be challenging to read whats on labels as they fade in a medicine cabinet.

Crystal Polson, a nurse practitioner and founder of patient advocacy blog Prudent Patient, pointed out that bathroom conditions can degrade whats outside and inside medicine containers. Many medications are sensitive to heat and moisture from your shower, bath or sink. They can break down from the humidity or become less potent due to the change in temperature, she said.

Polson said its best to store your medications in a cool, dry place. If there are young children around, be sure to keep drugs in a locked box or cabinet, she added.

4. Retinol and vitamin C-based products

Skin care products that contain retinol should never be stored in a medicine cabinet, Trauco said. Light, air and heat alter the chemical structure of retinol, limiting its efficacy. And the same goes with vitamin C-infused products.

Skin care products filled with vitamin C are very popular, Trauco said. Unfortunately, heat reduces its potency, so store those serums and moisturizers someplace else, away from heat and light.

5. Emergency medications

Tiffany Parker, an emergency nurse in Jacksonville, North Carolina, said to keep the following out of your medicine cabinet: EpiPens, sublingual nitroglycerine tablets, rescue inhalers, insulin, glucose tablets, and blood glucose level measuring supplies for diabetics.

Those should never be left in the medicine cabinet because there is a potential to forget and leave the house without them, Parker explained.

She recommended keeping these items in a purse or an easily carried go bag so you are never without these lifesaving supplies. (Just dont leave them in a hot car or somewhere that puts them at risk.)

6. Your toothbrush

5second via Getty Images

Kathy Frerk, a registered nurse in Sioux Falls, South Dakota, explained that a cabinet can hoard the heat and humidity of your bathroom, allowing harmful organisms to grow. That can be bad news for a device that you then stick in your mouth.

After using, store your toothbrush standing upright so it can air dry and not harbor moisture, Frerk said. And to cut down on gum disease, Frerk also recommended soaking your toothbrush in Listerine to kill bacteria. And dont forget to replace your toothbrush every three months.

7. Used razor blades

How many times have you tossed your razor into your medicine cabinet, then pulled it out later to reuse over and over for longer than you should?

An old blade and irritated skin is a dangerous combination and just because you dont see the cuts on your skin doesnt mean theyre not there, Cayo said. She added that this is because a worn-out blade can cause microscopic tears in your skin and introduce bacteria, which in turn can increase the risk for infection.

Some tips for helping to keep your razor blade clean include rinsing it with warm water between strokes to remove hair clogging it, towel drying it once you finish shaving, and allowing it to air out when you store it. (Avoid closed-off cabinets.) Experts also suggest replacing a disposable razor blade after every five to 10 uses, and refraining from sharing one with a friend or family member.

8. Gummy vitamins

This is more of an access issue. Gummy vitamins taste like candy, and you dont want kids going into the medicine cabinet looking for them, Parker explained. Medicine cabinets are easy to get into for young children, and they may take it upon themselves to eat the vitamins when theyre not under supervision. And ingesting too many vitamins can be extremely toxic, Parker said. She recommended storing them out of a kids reach and with a childproof lid.

9. Hydrogen peroxide or rubbing alcohol

Jummie via Getty Images

This is something Polson said she generally avoids keeping around in her bathroom, medicine cabinet or otherwise.

Why? Contrary to popular belief, these two agents are not appropriate for cleaning minor cuts and scrapes. In fact, they can both harm skin tissue and delay wound healing, Polson said.

She added that the best way to take care of a minor injury is with clean water and mild soap. Sticking your cut under cool water, gently lathering up, and rinsing it for five minutes can do the job of removing any debris, bacteria and dirt. And an emergency physician should handle larger or deeper cuts.

10. Liquid bandage

This specific product is not something that Catherine Burger, a registered nurse and media specialist for RegisteredNursing.org, recommended having in your medicine cabinets first aid kit. While a liquid bandage-based product can work on cuts if administered correctly, its often not applied well at home in a hurry.

We have had to pick these products out of too many infected wounds. Plus, the products can be very painful for superficial cuts, Burger explained.

They also have an array of potential side effects, including hives, itching, skin redness and a stinging sensation. Best to stick with regular bandages if youre unsure.

Read more here:

10 Things Nurses Would Never Keep In Their Medicine Cabinets - HuffPost

Joseline Hernandez Made Her Married To Medicine Debut This Week And Already Has An Enemy – BET

Joseline Hernandez's Love & Hip Hop days may be over, but the reality TV icon isn't done shaking the table just yet. To prove that, she is set to make her debut on Bravo's Married to Medicine on Sunday, September 29, and judging from a preview clip of the episode, she wasted no time stirring the pot.

In a clip from the upcoming episode, the self-proclaimed Puerto Rican princess is seen getting into it with OG cast memberToya Bush-Harrisover their views on mothering.

"I call it being a mother, I don't think it's a job," Hernandez said, to which Bush-Harris rebutted, "Being a mother is a full-time job."

The Love & Hip Hop star then took their seemingly civilized disagreement to new heights when she used Bush-Harris' reported tax woes as ammunition.

"But, you know, we're gonna keep letting you live it up, not paying your taxes," she said.

Take a look at the brief preview, below:

For those confused about Hernandez's random appearance on the hit Bravo reality series, she was brought on as a friend toMarried to Medicine newcomer Buffie Purselle, a personal finance and tax professional and the wife of well-known psychiatrist Dr. David Purselle.

In response to the shady clip, she claimed she only took such a sharp approach because Harris came for Purselle first.

"Don't come for my sister @BuffiePurselle or you will get the business," she tweeted.

There's never a dull moment with this lady, no matter where she goes.

Here is the original post:

Joseline Hernandez Made Her Married To Medicine Debut This Week And Already Has An Enemy - BET

Married To Medicine Recap: Ballin On A Budget – Reality Tea

On last nights episode of Married to Medicine, there was a little bit of everything. You have reconciliations, budgets and of course some drama. Im starting to think its weird when there isnt an issue, because its so rare.

Jackie Walters and Curtis have big dreams for their house, but are finding out their budget may be too small for their plans. Contessa Metcalfes family is having a difficult time with her being away in Nashville. Simone Whitmores friend, Buffie throws a party and things go downhill fast with some of the guests. Are we surprised? It wouldnt be a true Married to Medicine episode, without a little shade!

Jackie and Curtis to discuss the renovations they want to be made to their home. They both have very different taste in decor. Curtis thinks some of Jackies choices are too much, including the chandelier in the closet. Jackie is just happy to finally get to work on some of the changes she has wanted for the house. Curtis will just have to deal. He is lucky that they arent in a condo in the city.

Scott Metcalfe and Contessa take the kids to the park for some quality time. Contessa doesnt feel like Scott is as emotionally supportive of the kids as she is. I just think Contessa needs to give poor Scott a break. They are two different parents and arent going to always do things the same way. The kids even admit that they dont like that shes away in school. Her youngest daughter tells Contessa that she sometimes forgets about her when shes not around. Wow that has to hurt.

Buffie decides to throw another end of tax season party. The theme requires everyone to have a $500 limit for their outfits. On the way to the party, Quad Webb-Lunceford discusses Simone withHeavenly Kimes. Meanwhile, Simone talks to Jackie about her issues with Quad. Both ladies think they are owed an apology. When Quad and Simone see each other they agree to work out their problems, despite their recent blowup. Of course,Mariah Huq has to throw a dig when she sees Heavenly. She tells Heavenly that cheap dresses look good on her.

When I saw Joseline Hernandez at this party, I knew nothing good would come of it. Apparently, she has been a client and friend of Buffies for the past 5 years. Joseline clashes with Toya Bush-Harris after she says being a mother is a full-time job. Joseline takes the opportunity to shade Toya about her past tax debt and tell her she looks thrifty. Toya warns Joseline to stay out of her personal business. Mariah has to take Toya to the bathroom to calm her down. Buffie attempts to apologize for Joselines actions. Joseline went off on Eugene Harrisas well. When he told her not to call his wife a hoe, Joseline went off. Frustrated with the drama, Toya and Eugene decide to leave. Well, I cant say Im surprised.

Mariah meets up with Toya to discuss the party. Toya didnt like how Buffie handled the situation with Joseline. At this point, she has no desire to move forward with Buffie. If anyone has seen Joseline on Love and Hip Hop they know, she can be a lot to deal with. I am questioning why Buffie would even think it was a good idea to invite her. Nonetheless, Toya is looking forward to her upcoming birthday party.

Toya decides to have a sip and paint event for her 43rd birthday. She even invites Contessa. However, she leaves Buffie off of her invitation list. Look how things have changed. Toya wants to move on from her past issues with Contessa. The two even hug when Contessa arrives. Simone brings Buffie to the party anyway. Toya isnt happy, but Simone hopes she will give Buffie another chance.

At the beginning of the event, Toya reveals that she had a miscarriage. After dealing with the loss, she wanted to have something that was positive. Buffie gives Toya a hug and offers condolences. Then nude male models come out. I guess it wouldnt be Toya if there wasnt a twist to the evening.Heavenly decides not to tell her husband about that part of the night.

Im glad Toya finally told everyone what she has been going through lately. Maybe in the future they will be nicer to one another. You never know what someone else is dealing with personally. I doubt this group will totally mend all their issues, but its nice when they can come together.

TELL US SHOULD CONTESSA PUT HER KIDS DESIRES ABOVE HER OWN? DID BUFFIE HANDLE THE ARGUMENT BETWEEN TOYA AND JOSELINE THE WRONG WAY? DO YOU THINK QUAD AND SIMONES TRUCE WILL LAST? WHAT DID YOU THINK ABOUT LAST NIGHTS MARRIED TO MEDICINE EPISODE?

[Photo Credit: Bravo]

More here:

Married To Medicine Recap: Ballin On A Budget - Reality Tea

Why drug trials are only part of the answer to making sure medicines work – The Conversation – UK

There was a moment when, as a pharmacist, I realised that a lot of people to whom I gave medicine were going to receive little benefit, or even none at all. Healthcare staff make clinical decisions of when to use one medicine or another based upon evidence drawn from clinical trials. Clinical trials give us the data that show the probability that a medicine will have the desired effect but there is also the chance that it will not.

Clinical trials are a good way of identifying drugs that, on the whole, are effective at achieving a specific outcome. But on the whole doesnt take into account the wide variation among humans that means patients may react very differently to the drugs theyre given. The promise of personalised medicine is that through a more accurate understanding of a patients genetic makeup, alongside factors such as their lifestyle, diet and environment, they can be prescribed different drugs depending on what we know about how those drugs will affect them personally, rather than on the whole.

Clinical trial data are based on probabilities. Most controlled trials test a drug against a placebo or an existing drug, and the outcomes such as not having a heart attack, or experiencing a side effect are counted up to compare.

The likelihood that a patient will experience an event is known as absolute risk. This is calculated by dividing the number of events by the number of people. For example, if eight of a group of 100 people have a heart attack in a single year, the absolute risk is 8/100 = 0.08 (or 8%). Say that during a drug trial the absolute risk for those given the drug is 0.03, and for the placebo group it is 0.08, the drug on trial would be said to have achieved an absolute risk reduction of 0.05 (or 5%).

However, there is a risk that people experience an event whether or not they are taking the drug. This relative risk is calculated by dividing the absolute risk of the group taking the drug by the absolute risk of the control group given the placebo. The drugs efficiency taking into account background risk the relative risk reduction is calculated by dividing the absolute risk reduction by the absolute risk of the placebo group. Using the same example above, it would be 0.05/0.08, or 0.625 (or 62.5%).

Crucially, if you are in the business of manufacturing and selling medicines, expressing a drugs effectiveness by its relative risk reduction offers a better impression than by its absolute risk: lets face it, a reduction of 62.5% sounds much more impressive than a reduction of 5%.

Read more: Personalised medicine: how science is using the genetics of disease to make drugs better

Using these methods on clinical trial data help us gauge the effectiveness of medicines, but they dont take into account the differences among the patients taking them. Through genetic variation, human bodies vary considerably in the way they interact with drugs, potentially making them more effective, less effective, or something else entirely. For example, people with high cholesterol, something that runs in families, are in the UK currently offered DNA testing to confirm their diagnosis, and start treatment much earlier.

To see how much these factors affect how medicines work: an estimate of the number of people that must take a drug for one person to get the desired outcome is known as the number needed to treat. Using the same example of a drug trial with an absolute risk reduction of 0.05 (5%), this means that, statistically, 20 people (20x5%=100%) would need to be given the drug for one to feel the benefits. As we dont know which of the 20 will benefit from taking the drug, we must give it to all of them.

This is a problem because medicines are not without harms: almost all have side effects, which the other 19 may suffer even without experiencing the drugs benefits. This is known as number needed to harm, where harm could be anything from headaches and rashes to internal bleeding or even death. Clearly, if taking a medicine you would want to know that the benefit outweighs the harm.

Read more: Why I donated my entire genome sequence to the public

As an example, statins are drugs commonly used to lower cholesterol and reduce the risk of having heart attacks and strokes. The drug will reduce the relative risk of heart attack or stroke by about 25%, but may also generate side effects. The patient and prescriber need to balance the benefit versus the harm. This decision can be guided using patient decision aids, developed to help patients understand the balance of benefits and harms in the context of how they may have to change their lifestyle while taking the medicine.

There has been interest in a recent trial of the polypill, a tablet containing blood pressure-lowering medicine and a statin, which was given to around 3,400 people over the age of 50 in Golestan province, Iran. At a population level it led to a reduction in cardiovascular events, but the same approach will also mean more people will experience side effects compared to an approach that targets only those at high risk. In low and middle-income countries that lack the resources to diagnose and target many individuals, this may be a price worth paying.

Which brings us back to the promise of personalised medicine: ideally we would be able to identify the hypothetical one in 20 patients given a drug that benefit from it, and prescribe the medicine to them alone. Beyond the benefit to the patient, there are cost benefits to the health service and to society, but chiefly there are benefits for the other 19 who need not take a drug that wont benefit them and may cause them side effects or adverse drug interactions. Better understanding of our genome and how it affects our risk of disease will provide the tools to identify those most at risk, and target them alone.

The rest is here:

Why drug trials are only part of the answer to making sure medicines work - The Conversation - UK

MIT.nano awards inaugural NCSOFT seed grants for gaming technologies – The MIT Tech

MIT.nano has announced the first recipients of NCSOFT seed grants to foster hardware and software innovations in gaming technology. The grants are part of the new MIT.nano Immersion Lab Gaming program, with inaugural funding provided by video game developer NCSOFT, a founding member of the MIT.nano Consortium.

The newly awarded projects address topics such as 3-D/4-D data interaction and analysis, behavioral learning, fabrication of sensors, light field manipulation, and micro-display optics.

New technologies and new paradigms of gaming will change the way researchers conduct their work by enabling immersive visualization and multi-dimensional interaction, says MIT.nano Associate Director Brian W. Anthony. This years funded projects highlight the wide range of topics that will be enhanced and influenced by augmented and virtual reality.

In addition to the sponsored research funds, each awardee will be given funds specifically to foster a community of collaborative users of MIT.nanos Immersion Lab.

The MIT.nano Immersion Lab is a new, two-story immersive space dedicated to visualization, augmented and virtual reality (AR/VR), and the depiction and analysis of spatially related data. Currently being outfitted with equipment and software tools, the facility will be available starting this semester for use by researchers and educators interested in using and creating new experiences, including the seed grant projects.

The five projects to receive NCSOFT seed grants are:

Stefanie Mueller: connecting the virtual and physical world

Virtual game play is often accompanied by a prop a steering wheel, a tennis racket, or some other object the gamer uses in the physical world to create a reaction in the virtual game. Build-it-yourself cardboard kits have expanded access to these props by lowering costs; however, these kits are pre-cut, and thus limited in form and function. What if users could build their own dynamic props that evolve as they progress through the game?

Department of Electrical Engineering and Computer Science (EECS) Professor Stefanie Mueller aims to enhance the users experience by developing a new type of gameplay with tighter virtual-physical connection. In Muellers game, the player unlocks a physical template after completing a virtual challenge, builds a prop from this template, and then, as the game progresses, can unlock new functionalities to that same item. The prop can be expanded upon and take on new meaning, and the user learns new technical skills by building physical prototypes.

Luca Daniel and Micha Feigin-Almon: replicating human movements in virtual characters

Athletes, martial artists, and ballerinas share the ability to move their body in an elegant manner that efficiently converts energy and minimizes injury risk. Professor Luca Daniel, EECS and Research Laboratory of Electronics, and Micha Feigin-Almon, research scientist in mechanical engineering, seek to compare the movements of trained and untrained individuals to learn the limits of the human body with the goal of generating elegant, realistic movement trajectories for virtual reality characters.

In addition to use in gaming software, their research on different movement patterns will predict stresses on joints, which could lead to nervous system models for use by artists and athletes.

Wojciech Matusik: using phase-only holograms

Holographic displays are optimal for use in augmented and virtual reality. However, critical issues show a need for improvement. Out-of-focus objects look unnatural, and complex holograms have to be converted to phase-only or amplitude-only in order to be physically realized. To combat these issues, EECS Professor Wojciech Matusik proposes to adopt machine learning techniques for synthesis of phase-only holograms in an end-to-end fashion. Using a learning-based approach, the holograms could display visually appealing three-dimensional objects.

While this system is specifically designed for varifocal, multifocal, and light field displays, we firmly believe that extending it to work with holographic displays has the greatest potential to revolutionize the future of near-eye displays and provide the best experiences for gaming, says Matusik.

Fox Harrell: teaching socially impactful behavior

Project VISIBLE Virtuality for Immersive Socially Impactful Behavioral Learning Enhancement utilizes virtual reality in an educational setting to teach users how to recognize, cope with, and avoid committing microaggressions. In a virtual environment designed by Comparative Media Studies Professor Fox Harrell, users will encounter micro-insults, followed by major micro-aggression themes. The users physical response drives the narrative of the scenario, so one person can play the game multiple times and reach different conclusions, thus learning the various implications of social behavior.

Juejun Hu: displaying a wider field of view in high resolution

Professor Juejun Hu from the Department of Materials Science and Engineering seeks to develop high-performance, ultra-thin immersive micro-displays for AR/VR applications. These displays, based on metasurface optics, will allow for a large, continuous field of view, on-demand control of optical wavefronts, high-resolution projection, and a compact, flat, lightweight engine. While current commercial waveguide AR/VR systems offer less than 45 degrees of visibility, Hu and his team aim to design a high-quality display with a field of view close to 180 degrees.

Read the original:

MIT.nano awards inaugural NCSOFT seed grants for gaming technologies - The MIT Tech

Impressive Growth of Biomedical Nanotechnology Market 2019-2025 Upcoming Developments, Business Predictions & Future Investment Including Advanced…

Biomedical Nanotechnology is a rapidly developing field, which includes a diverse collection of disciplines. The applications of nanotechnology are gaining an overwhelming response in almost all the fields. Especially in the healthcare sector, tremendous developments have been achieved. For example, cancer diagnosis and therapy, medical implants, tissue engineering etc.

Report Consultant has added a new report to its database that qualifies an expressive and professional look into this market. The report is titled Global Biomedical Nanotechnology Market. Thus, the report scrutinizes the present-day environment of the market in order to generate a comprehensive understanding of the future plans of the market. The Global Biomedical Nanotechnology Market report consists of enormous databases related to the traders and manufacturers who have high mechanical and specialized ranges of abilities, which are attributed to be the key factors responsible for the growth of the market.

Request A Sample Copy Of Report: Click Here https://www.reportconsultant.com/request_sample.php?id=5743

Top Key Players:

Advanced Nano Products Co. Ltd, Altair Nanotechnologies Inc., Arrowhead Pharmaceuticals Inc., Bruker Corp, Catalytic Materials LLC, Chemat Technology Inc., eSpin Technologies Inc., ELITech Group, Genefluidics Inc., Hanwha Nanotech Corporation, Hybrid Plastics, Hyperion Catalysis International Inc., Integran Technologies Inc., Intrinsiq Materials Ltd (IML).

This Global Biomedical Nanotechnology Market report focuses on the requirements of the clients from several global regions such as North America, Latin America, Asia-Pacific, Europe, and India. Facts and figures about various financial terms have been analyzed by considering several key points such as prices, market shares, and profit margin. It examines the different modules for evaluation of the risks and threats. The productivity of several industries has been scrutinized by considering the different factors.

This Global Biomedical Nanotechnology Market report focuses on the advancements of technological platform, tools, and methodologies which helps to provide proper guidelines to the businesses. Apart from this, it gives a detailed description of effective sales strategies which helps to discover global clients rapidly. Different key pillars are fueling the growth of the Global Biomedical Nanotechnology Market. It offers some significant factors which are responsible for restraining the progress of the market sector. To explore the numerous global opportunities several methodologies have been mentioned in this report.

Ask For Discount@ https://www.reportconsultant.com/ask_for_discount.php?id=5743

Biomedical Nanotechnology Market Segment By Type, The Product Can Be Split Into

Biomedical Nanotechnology Market Segment By Application, Can Be Split Into

Segment By Regions/Countries, This Biomedical Nanotechnology Market Report Covers

In This Study, The Years Considered To Estimate The Market Size Of Biomedical Nanotechnology Are As Follows:

Table Of Content:

The Global Biomedical Nanotechnology Market Report Contains:

For More Information: Click Here https://www.reportconsultant.com/enquiry_before_buying.php?id=5743

Contact us:

Rebecca Parker

(Report Consultant)

13284 Bluejacket Street Overland Park,

KS 66213 United States

Contact No: +1 620-220-2270

sales@reportconsultant.com

http://www.reportconsultant.com

See the original post:

Impressive Growth of Biomedical Nanotechnology Market 2019-2025 Upcoming Developments, Business Predictions & Future Investment Including Advanced...